Nature子刊：中科大孙成团队发现癌症免疫治疗新靶点——CLEC12B

Core Viewpoint - The research identifies CLEC12B as an inhibitory checkpoint in NK cells, which limits their anti-tumor immune response, and proposes a novel therapeutic strategy targeting this pathway to enhance cancer immunotherapy [2][4]. Group 1: Research Findings - The study published in Nature Immunology reveals that high expression of CLEC12B in tumor-infiltrating NK cells of liver cancer patients correlates with poor clinical prognosis [4]. - The research team discovered that lipoprotein lipase acts as a functional ligand for CLEC12B, triggering inhibitory signaling that suppresses NK cell activation [4]. - A high-affinity nanobody was developed to disrupt the CLEC12B-lipoprotein lipase signaling axis, restoring NK cell activity and inhibiting tumor progression in preclinical models [4]. Group 2: Therapeutic Implications - The nanobody shows strong synergistic efficacy when used in combination with PD-1 blockade, establishing CLEC12B as a promising therapeutic target for rearming the immune system against solid malignancies [4].